ישראל - עברית - Ministry of Health

abbvie biopharmaceuticals ltd, israel - upadacitinib as hemihydrate - טבליות בשחרור ממושך - upadacitinib as hemihydrate 15 mg - upadacitinib

ישראל - עברית - Ministry of Health

abbvie biopharmaceuticals ltd, israel - upadacitinib as hemihydrate - טבליות בשחרור ממושך - upadacitinib as hemihydrate 15 mg - upadacitinib

ישראל - עברית - Ministry of Health

abbvie biopharmaceuticals ltd, israel - upadacitinib as hemihydrate - טבליות בשחרור ממושך - upadacitinib as hemihydrate 30 mg - upadacitinib

ישראל - עברית - Ministry of Health

abbvie biopharmaceuticals ltd, israel - upadacitinib as hemihydrate - טבליות בשחרור ממושך - upadacitinib as hemihydrate 45 mg - upadacitinib

ישראל - עברית - Ministry of Health

pfizer pharmaceuticals israel ltd - tofacitinib as citrate - טבליות עם שחרור נרחב - tofacitinib as citrate 11 mg - tofacitinib

ישראל - עברית - Ministry of Health

k.s.kim international (sk- pharma) ltd., israel - bortezomib as mannitol boronic ester - אבקה להכנת תמיסה לזריקה - bortezomib as mannitol boronic ester 3.5 mg - bortezomib

ישראל - עברית - Ministry of Health

unipharm trading ltd, israel - sugammadex as sodium - תמיסה להזרקה - sugammadex as sodium 100 mg / 1 ml - sugammadex

ישראל - עברית - Ministry of Health

a.l. medi-market ltd. - atosiban as acetate - atosiban as acetate 7.5 mg/ml - atosiban

ישראל - עברית - Ministry of Health

a.l. medi-market ltd. - dexmedetomidine as hydrochloride - תרכיז להכנת תמיסה לאינפוזיה - dexmedetomidine as hydrochloride 100 mcg / 1 ml - dexmedetomidine

ישראל - עברית - Ministry of Health

pfizer pharmaceuticals israel ltd - etanercept - אבקה וממס להכנת תמיסה להזרקה - etanercept 25 mg/vial - etanercept - etanercept - * rheumatoid arthritis:enbrel is indicated for the treatment of active rhematoid arthritis in adults when the response to disease-modifying antirheumatic drugs (dmards) including methotrexate (unless contraindicated) has been inadequate.. enbrel can be used in combination with methotrexate in patients who do not respond adequately to methotrexate alone. reducing signs and symptoms and inhibiting the progression of structural damage in patients with moderately to severely active rheumatoid arthritis.enbrel, alone or in combination with methotrexate, has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function.* polyarticular juvenile idiopathic arthritis: treatment of active polyarticular juvenile idiopathic arthritis in children and adolescents from the age of 2 years who have had an inadequate response to, or who have proved intolerant of, methotrexate. enbrel has not been studied in children aged less than 2 years.* psoriatic arthritistreatment of ac